Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033163 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL1033074 | 0.94 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL1031040 | 0.91 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL1034629 | 0.91 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL1033487 | 0.91 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL1031077 | 0.88 | TP53 (0.50) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL1034229 | 0.88 | TP53 (0.50) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL1034622 | 0.86 | MAPT (0.51) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL1029196 | 0.85 | GAA (0.43) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL1034939 | 0.85 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981913-B2 | Liver X receptor (LXR) modulators | RALEXAR THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981913-B2 | Liver X receptor (LXR) modulators | RALEXAR THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | RALEXAR THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | RALEXAR THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| EP-1572660-B1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7265131-B2 | Isoquinolinone derivatives and their use as therapeutic agents | EXELIXIS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1572660-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | X-CEPTOR THERAPEUTICS INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004058717-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | NR1H2, NR1H3, RXRB | ALDH1A1 1132/4885KMT2A 3260/4885MEN1 4799/4885 |
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | NR1H2, NR1H3, NR1I2 | ALDH1A1 601/4885KMT2A 3097/4885MEN1 4349/4885 |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | NR1H2, NR1I2, NR1H3 | ALDH1A1 415/4885KMT2A 3367/4885MEN1 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.